Patients with COVID-19 Interstitial Pneumonia Exhibit Pancreatic Hyperenzymemia and Not Acute Pancreatitis
Autor: | Matteo Davì, Raffaele Pezzilli, R. Stefanelli, Rocco Francesco Rinaldo, Alessandra Barassi, Michele Mondoni, Stefano Centanni, Gianvico Melzi d'Eril |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
biology Nausea business.industry medicine.disease Gastroenterology 03 medical and health sciences Diarrhea 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine medicine Vomiting biology.protein Acute pancreatitis Pancreatitis 030211 gastroenterology & hepatology Amylase medicine.symptom Lipase Respiratory system business |
DOI: | 10.21203/rs.3.rs-50275/v1 |
Popis: | Background: Gastrointestinal manifestations of COVID-19 have been well established, but pancreatic involvement is under debate To evaluate the presence of acute pancreatitis in COVID-19 patient in a prospective, unicenter cohort study Methods: From April 1, 2020 to April 30, 2020, 110 consecutive patients (69 males, 41 females;mean age 63 0 years [range, 24-93 years]) met these criteria and were enrolled in the study The clinical data and serum activity of pancreatic amylase and lipase were assayed in all patients using commercially available kits Results: The average time from the onset of respiratory symptoms to the blood samples was 22 2 days (range, 0-47) None of the patients studied developed clinical signs ormorphological alterations compatiblewith acute pancreatitis according to the Atlanta revised criteria It was found that 24 5% of the patients had amylase values above 53 IU/L and 16 4% had lipase values above 300 IU/L Only one patient (0 9%) had both amylase and lipase values in excess of three-fold the upper normal limit without clinical signs of pancreatitis There were no statistically significant difference in amylase and lipase serum activities in patients having nausea/vomiting (amylase: 32 1 ± 18 7 IU/L, P = 0 438;lipase: 80 7 ± 42 4 IU/L, P = 0 134) and in those who did not (amylase: 46 3 ± 35 7 IU/L;lipase: 200 3 ± 240 0 IU/L), or in patients having diarrhea (amylase: 65 4 ± 64 2 IU/L, P = 0 198;lipase: 303 0 ± 544 4 IU/L, P = 0 615) and in those who did not (amylase: 43 1 ± 28 5 IU/L;lipase: 181 5 ± 149 3 IU/L) Regarding the oxygen support, a statistical difference was found in amylase serum activities among the various types of oxygen support used (amylase P = 0 047) whereas this difference was not found for lipase (P = 0 065) Conclusions: The presence of pancreatic hyperenzymemia in a patient with COVID-19 requires the management of these patients be guided by clinical evaluation and not merely by evaluation of the biochemical results |
Databáze: | OpenAIRE |
Externí odkaz: |
načítá se...